
Last week, HC Wainwright hosted Voyager Therapeutics, Inc.’s (NASDAQ:VYGR) management during HCW's Annual Global Investment Conference.
The management emphasized recent preclinical murine data from a head-to-head study showing that its alkaline phosphatase (ALPL) receptor-mediated non-viral NeuroShuttle sustained central nervous system (CNS) exposure for more than 3 weeks compared to less than 1 week with transferrin receptor shuttles, highlighting durability and a potential safety advantage.